Guardant Health’s Shield Blood Test Gains Coverage from Carelon, Expanding Access to 90 Million — Guardant Health, Inc.

Event summary

Guardant Health’s Shield blood test for colorectal cancer screening will be covered by Carelon Healthcare Services effective November 15, 2026.
The coverage expansion brings total covered lives for Shield to approximately 90 million, or 75% of all eligible patients for CRC screening in the U.S.
Shield is the first FDA-approved blood test for primary colorectal cancer screening in average-risk adults age 45 and older.
Carelon provides medical benefit management to Blue Cross Blue Shield plans across 26 states.

The big picture

Guardant Health’s Shield blood test is gaining traction as a non-invasive alternative to traditional colorectal cancer screening methods. The coverage expansion by Carelon Healthcare Services underscores the growing acceptance of blood-based screening options, particularly as colorectal cancer rates rise among younger adults. This strategic move positions Guardant Health to capture a significant share of the CRC screening market, leveraging its FDA approval and clinical validation to drive adoption.

What we're watching

Market Penetration: The pace at which Guardant Health can expand Shield’s coverage to remaining eligible patients and new markets.
Regulatory Dynamics: Whether the inclusion of Shield in American Cancer Society and National Comprehensive Cancer Network guidelines will drive further adoption.
Execution Risk: How Guardant Health will manage the operational challenges of scaling Shield’s usage amid rising colorectal cancer rates in younger adults.